Phaseline

Targets › TNFRSF9

TNFRSF9 (Tumor necrosis factor receptor superfamily member 9): drug programs, companies and trials

7 programs from 7 companies in 11 trials: 7 Phase 2, 2 Phase 3, 2 Phase 1; Oncology; next expected readout Dec 2026.

Receptor for TNFSF9/4-1BBL. Conveys a signal that enhances CD8(+) T-cell survival, cytotoxicity, and mitochondrial activity, thereby promoting immunity against viruses and tumors (Probable). (UniProt, Q07011)

Open in Phaseline: the race on TNFRSF9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerUtomilumab
Tumor necrosis factor receptor superfamily member 9 agonist
TNFRSF9Phase 3Advanced Malignancies; Stage III Breast Cancer; Breast Cancer; Advanced Malignant Solid NeoplasmDec 2026
GenmabAcasunlimab
Bispecific antibody that engages PD-L1 and 4-1BB
CD274, TNFRSF9Phase 3PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLCJul 2027
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsUrelumab
Tumor necrosis factor receptor superfamily member 9 agonist
TNFRSF9Phase 2Pancreatic Cancer; Urothelial CarcinomaDec 2026
Lyvgen Biopharma HoldingsLVGN6051
4-1BB agonistic antibody
TNFRSF9Phase 2Head and Neck Squamous Cell CarcinomaOct 2027
Fudan UniversitySHR-1701
4-1BB agonist monoclonal antibody
TNFRSF9Phase 2Prostate CancerMar 2028
Pieris PharmaceuticalsCinrebafusp alfa (PRS-343)
HER2/4-1BB bispecific antibody
ERBB2, TNFRSF9Phase 2HER2-positive Gastric Cancer–
Bangdong GongiC9/CAR19/IL15 CB-NK cell
Chimeric Antigen Receptor Natural Killer Cell targeting CD19 with inducible suicide gene (
TNFRSF9, CD19, IL15Phase 1Primary Sjogren's SyndromeOct 2027

Conditions

Advanced Malignancies (1) Stage III Breast Cancer (1) Breast Cancer (1) Advanced Malignant Solid Neoplasm (1) Head and Neck Squamous Cell Carcinoma (1) Primary Sjogren's Syndrome (1) Pancreatic Cancer (1) Urothelial Carcinoma (1) PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC (1) HER2-positive Gastric Cancer (1) Prostate Cancer (1)

Modalities

mixed (4), other (1), antibody (1), small molecule (1)

Companies

Pfizer (1) Lyvgen Biopharma Holdings (1) Bangdong Gong (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) Genmab (1) Pieris Pharmaceuticals (1) Fudan University (1)

Related targets

CD19 (1) IL15 (1) CD274 (1) ERBB2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.